Company Overview and News

 
Mico Chung, the upstart Hong Kong developer who aims to join the ‘big boys’ league

2018-05-11 scmp
Once touted as ‘Richard Li’s right-hand man’, does one of Hong Kong’s savviest deal makers have what it takes to found a new property empire to rival that of Henderson or New World?

 
Richard Li’s Pacific Century marks return to property development after 10 year absence

2018-01-16 scmp
Richard Li Tzar-kai’s Pacific Century Premium Developments will partner with Hong Kong-listed CSI Properties to jointly develop a prime residential site near the city’s main business and nightlife hubs.

 
Richard Li poised to take over £6 billion north London project, in his first foray into UK property

2017-11-02 scmp
The project’s value would top the HK$40.2 billion price that Li’s father fetched for selling The Center office tower in Hong Kong.

 
PCCW charts plans to expand media, IT services footprint

2017-01-16 scmp
PCCW, the flagship company of tycoon Richard Li Tzar-kai, is looking to expand its regional presence in the media and IT services businesses after reporting a 1 per cent increase in core profit for 2016.

 
PCCW's Shares Worth More Than The Current Price

2016-11-30 seekingalpha
PCCW's net asset value (calculated using SOTP) is at least 53% higher than its current market cap.

 
The 10 Best, Largest Net-Nets That Can Be Traded With Interactive Brokers

2016-09-18 seekingalpha
This is not true. In this article, I describe 10 liquid net-nets with market caps above 100 million USD.

 
Hong Kong’s Richest Man Isn’t Worried About the Survival of His $80 Billion Empire - Bloomberg

2016-06-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...